Subscribe to Onlymyhealth Newsletter
  • I have read the Privacy Policy and the Terms and Conditions. I provide my consent for my data to be processed for the purposes as described and receive communications for service related information.

German firm is on its way to rolling out a new diabetes drug

German firm is on its way to rolling out a new diabetes drug

A German company Boehringer Ingelheim, will soon be rolling a patented diabetes drug during the month of October and November. This hot-selling segment of a new class of pills that will be used for the treatment of type 2 diabetes will be called “India-friendly” price.

Diabetes drug

Jardiance (empagliflozin) is a once-a-day treatment that will cost Rs 45 for a day’s therapy, which will cost approximately Rs 1, 300 per month. It will compete with other newer drugs in the Rs 1500-crore-anti-diabetes market that comprises medicines such as gliptins.

The anti-diabetes market is the fifth largest therapy in the domestic retail market, which stands at Rs 7, 400 crore and is growing at 25 percent. It is not easy therefore, to find an affordable pricing on a particular drug for all the segments of the population. The same drug is priced 20 times more in the US, said Boehringer Ingelheim India managing director Sharad Tyagi.

Read more health news.
Image source: Getty

Written by
Bhadra Kamalasanan
Source: Onlymyhealth editorial teamSep 25, 2015

All possible measures have been taken to ensure accuracy, reliability, timeliness and authenticity of the information; however does not take any liability for the same. Using any information provided by the website is solely at the viewers’ discretion. In case of any medical exigencies/ persistent health issues, we advise you to seek a qualified medical practitioner before putting to use any advice/tips given by our team or any third party in form of answers/comments on the above mentioned website.

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK